The process of preparing GranuFlo lawsuit filings for trial is now underway, as the federal Massachusetts litigation begins to choose the first cases of its bellwether series.

According to court documents, a status conference scheduled for Friday, March 28th is slated to review proposals for a bellwether trial program designed to help gauge how juries will rule in similar actions against Fresenius Medical Care, a leading supplier of dialysis drugs and services. Plaintiffs’ and defendants’ proposals were each submitted to the U.S. District Court, District of Massachusetts on March 14, and detailed their positions on different aspects of the bellwether trial process. The parties agreed that a total of 20 lawsuits—ten chosen by each side—will enter a pool for trial, which will be then narrowed down to ten.

650+ GranuFlo Recall Lawsuits Filed in Massachusetts Litigation

Cases chosen for the bellwether trial program involve two acid concentrates affected by a NaturaLyte and GranuFlo recall in June 2012, an action that was taken by the U.S. Food and Drug Administration (FDA) after side effects associated with the medications were shown to be serious, and potentially fatal. A Case List updated on March 13th shows more than 650 lawsuits filed in the Massachusetts multidistrict litigation after an Urgent Product Notification from Fresenius warned about the risk heart attacks, strokes, sudden cardiac death and other serious cardiovascular injuries.

According the warning, GranuFlo and NaturaLyte side effects may stem from the drugs’ high consistency of an ingredient the body converts to bicarbonate, which may result in a condition referred to as metabolic alkalsosis. Given that these medications were administered in Fresenius dialysis centers across the U.S., as well as in some 125,000 customer clinics outside the company’s network, plaintiffs in dialysis lawsuits similarly allege that thousands of patients may have already been injured by the time of the March 29, 2012 warning.

It was also revealed at the time of the GranuFlo recall that Fresenius may have had prior knowledge of its products’ potential dangers, but waited several months before sharing them with the public. In November 2011, the company sent an internal memo to its dialysis clinics that warned of 941 deaths that followed use of dialysis treatments that used the acid concentrates. Doctors were told to adjust dosages of GranuFlo and NaturaLyte based on these findings.

Contact a GranuFlo Lawyer to File a Claim

Contact our Firm to learn more about the GranuFlo recall, and whether you may be eligible to file a claim against Fresenius. Call us today for a free and confidential case evaluation at (877) 779-1414.

Published March 27, 2014 by